This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

CUBE-C Coalition United for Better Eczema Care

CUBE-C Coalition United for Better Eczema Care


Expert Perspective

Time to Complete

1 hour


September 27, 2018


September 27, 2019
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

This activity is jointly provided by Global Education Group and FactorX.

Commercial Supporter

This activity is supported by educational grants provided by Sanofi Genzyme and Regeneron Pharmaceuticals; and Pfizer.

Program Description

This activity is part of the curriculum of the National Eczema Association's (NEA) Coalition United for Better Eczema Care (CUBE-C). The CUBE-C Initiative is designed to help providers usher in a new era of patient-centric care. In this activity, Dr. Doghramji, a family practice expert, leads a panel of Atopic Dermatitis (AD) experts and an adult patient with AD as they discuss the issues of diagnosis, treatment and management in the primary care setting. Special emphasis is placed on the importance of therapeutic patient education and the benefits of engaging patients in treatment choice.

Intended Audience

Dermatologists, allergists, pediatricians, primary care providers, nurse practitioners, physician assistants, and other healthcare providers involved in the diagnosis, management, and treatment of patients with atopic dermatitis (AD).

Educational Objectives

At the conclusion of this educational activity, participants should be able to:

  • Describe the clinical features of AD and distinguish it from other eczematous eruptions
  • Explain the pathogenesis and consequence of epidermal skin barrier defects
  • Recognize the allergic and non-allergic comorbidities of AD, including psychosocial comorbidities
  • Assess the role of bathing and moisturizing in improving the skin barrier defects in AD patients
  • Assess the benefits and risks of topical therapies for treating AD, including topical calcineurin inhibitors, anti-inflammatory ointments, antibiotics, and antihistamines
  • Restate the general recommendations for the use of topical corticosteroids in the management of AD
  • Contrast the mechanisms of action of emerging therapeutic approaches for the prevention and pharmaceutical management of AD
  • Recognize the value of integrating patient and caregiver education into routine practice

Conflict Of Interest Disclosure Policy

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.


Lawrence F. Eichenfield, MD
Professor of Dermatology and Pediatrics
Vice Chair, Department of Dermatology
Chief, Pediatric and Adolescent Dermatology
University of California, San Diego
School of Medicine

Dr. Eichenfield discloses the following:
Consultant/Independent Contractor: Allergan, Anacor/Pfizer, DS Biopharma, Galderma Labs, Genentech, Lilly, Otsuka/Medimetriks, Ralaxar, Regeneron/Sanofi, TopMD, and Valeant
Investigator: Regeneron/Sanofi
Advisory Board: Valeant
Speaker’s Bureau: Valeant

Jonathan Spergel, MD, PhD
Professor of Pediatrics
Perelman School of Medicine at University of Pennsylvania
Chief, Allergy Section
The Children’s Hospital of Philadelphia
Philadelphia, PA

Dr. Spergel discloses the following:
Consultant/Independent Contractor: DBV Technology and Dannone
Grant/Research Support: All payable to institution-NIH, FARE, AImmune
Speaker’s Bureau: MEI
Stock Shareholder: DBV Technology
Other/Royalty: Royalty-Uptodate

Paul Doghramji, MD, FAAFP
Senior Family Physician
Collegeville Family Practice
Medical Director
Ursinus College
Collegeville, PA

Dr. Doghramji has nothing to disclose.

Jenene Chesbrough
Brooklyn, NY

Accredited Provider Discosures

The planners and managers involved in the planning and content of this CME activity have no financial relationships to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group and FACTORx. This activity is in collaboration with National Eczema Association. Global is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Global Education Group designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and FACTORx do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Term of Offering

This activity was released on 9/27/2018 and is valid for one year. Requests for credit must be made no later than 9/27/2019.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.


To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue